Group | n | Baseline | 6 Months | 12 Months | Treatment effect | Between-group Pc
|
---|
Geometric Meana
| 95% CI | Geometric Mean | 95% CI | Geometric Mean | 95% CI | Ratio of High/Moderateb
| 95% CI |
---|
Intention-to-treat | 0.90 |
High | 195 | 9368 | 8720 – 10064 | 9353 | 8741–10008 | 9035 | 8467 – 9641 | 1.00 | 0.95 – 1.06 |
Moderate | 191 | 9331 | 8713 – 9992 | 9230 | 8644–9855 | 9017 | 8457 – 9613 | | |
Per-protocold
| 0.62 |
High | 80 | 8761 | 8002 – 9591 | 9158 | 8225–10198 | 8700 | 7904 – 9576 | 1.02 | 0.93 – 1.13 |
Moderate | 58 | 9653 | 8284 – 11248 | 9251 | 8110–10551 | 9366 | 8275 – 10600 | | |
-
aGeometric mean of prolactin was in the unit of pg/mL
-
bThe geometric mean ratios were estimated from least square means for the difference in treatment effect between high and moderate volume exercisers averaged across the entire study period adjusted for the baseline values and then back log-transformed
-
c
P value corresponds to the null hypothesis that the ratio of treatment effect between high- and moderate-volume groups equals 1 against the 2-sided alternative hypothesis
-
dWomen assigned to the moderate-volume group were adherent if they completed 90% to 100% of the exercise prescription (mean, 135–150 min/week), weeks 13 to 52 at full prescription; women assigned to the high-volume group were adherent if they completed at least 90% of the exercise prescription (mean, ≥270 min/week), weeks 13 to 52 at full prescription